Section Arrow
Quote
BPMC.NASDAQ
- Blueprint Medicines Corp
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 89.73
-0.99 (-1.09%)
Day High 
93.0399 
Prev. Close
90.72 
1-M High
96.72 
Volume 
651.99K 
Bid
81
Ask
120
Day Low
89.64 
Open
90.72 
1-M Low
84.59 
Market Cap 
5.80B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 90.79 
20-SMA 90.23 
50-SMA 98.9 
52-W High 121.9 
52-W Low 80.675 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.07/1.40
Enterprise Value
6.21B
Balance Sheet
Book Value Per Share
4.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
508.82M
Operating Revenue Per Share
3.38
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patientsliving with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.